• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2,4,6-三氨基嘧啶作为一系列PI3Kδ选择性抑制剂中的新型铰链结合剂。

2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors.

作者信息

Patel Leena, Chandrasekhar Jayaraman, Evarts Jerry, Haran Aaron C, Ip Carmen, Kaplan Joshua A, Kim Musong, Koditek David, Lad Latesh, Lepist Eve-Irene, McGrath Mary E, Novikov Nikolai, Perreault Stephane, Puri Kamal D, Somoza John R, Steiner Bart H, Stevens Kirk L, Therrien Joseph, Treiberg Jennifer, Villaseñor Armando G, Yeung Arthur, Phillips Gary

机构信息

Gilead Sciences, Inc. , 199 E Blaine Street, Seattle, Washington 98102, United States.

Gilead Sciences, Inc. , 333 Lakeside Drive, Foster City, California 94404, United States.

出版信息

J Med Chem. 2016 Apr 14;59(7):3532-48. doi: 10.1021/acs.jmedchem.6b00213. Epub 2016 Mar 29.

DOI:10.1021/acs.jmedchem.6b00213
PMID:26980109
Abstract

Inhibition of phosphoinositide 3-kinase δ (PI3Kδ) is an appealing target for several hematological malignancies and inflammatory diseases. Herein, we describe the discovery and optimization of a series of propeller shaped PI3Kδ inhibitors comprising a novel triaminopyrimidine hinge binder. Combinations of electronic and structural strategies were employed to mitigate aldehyde oxidase mediated metabolism. This medicinal chemistry effort culminated in the identification of 52, a potent and highly selective inhibitor of PI3Kδ that demonstrates efficacy in a rat model of arthritis.

摘要

抑制磷酸肌醇 3-激酶δ(PI3Kδ)是多种血液系统恶性肿瘤和炎症性疾病的一个有吸引力的靶点。在此,我们描述了一系列包含新型三氨基嘧啶铰链结合剂的螺旋桨状PI3Kδ抑制剂的发现和优化过程。采用电子和结构策略的组合来减轻醛氧化酶介导的代谢。这项药物化学研究最终确定了52,一种强效且高度选择性的PI3Kδ抑制剂,它在大鼠关节炎模型中显示出疗效。

相似文献

1
2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors.2,4,6-三氨基嘧啶作为一系列PI3Kδ选择性抑制剂中的新型铰链结合剂。
J Med Chem. 2016 Apr 14;59(7):3532-48. doi: 10.1021/acs.jmedchem.6b00213. Epub 2016 Mar 29.
2
Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.发现新型喹唑啉酮衍生物作为高效且选择性的 PI3Kδ 和 PI3Kδ/γ 抑制剂。
Eur J Med Chem. 2018 May 10;151:9-17. doi: 10.1016/j.ejmech.2018.03.068. Epub 2018 Mar 23.
3
Discovery, Optimization, and Evaluation of Quinazolinone Derivatives with Novel Linkers as Orally Efficacious Phosphoinositide-3-Kinase Delta Inhibitors for Treatment of Inflammatory Diseases.发现、优化和评估具有新型连接子的喹唑啉酮衍生物作为口服有效的磷酸肌醇 3-激酶 δ 抑制剂,用于治疗炎症性疾病。
J Med Chem. 2021 Jul 8;64(13):8951-8970. doi: 10.1021/acs.jmedchem.1c00004. Epub 2021 Jun 17.
4
SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.5-炔基取代喹唑啉-4(3H)-酮作为磷酸肌醇3-激酶δ(PI3Kδ)抑制剂的构效关系研究
Eur J Med Chem. 2017 Jan 5;125:1156-1171. doi: 10.1016/j.ejmech.2016.11.014. Epub 2016 Nov 9.
5
Evaluation of WO2014075392 and WO2014075393, Merck's first PI3Kδ inhibitor filings.评价默克公司的首个 PI3Kδ 抑制剂申请 WO2014075392 和 WO2014075393
Expert Opin Ther Pat. 2014 Nov;24(11):1277-82. doi: 10.1517/13543776.2014.969710.
6
Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.新型 6-芳基取代 4-吡咯烷氨基喹唑啉衍生物作为有效的磷酸肌醇 3-激酶 δ(PI3Kδ)抑制剂。
Bioorg Med Chem. 2018 May 1;26(8):2028-2040. doi: 10.1016/j.bmc.2018.03.002. Epub 2018 Mar 2.
7
Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors.作为选择性脾酪氨酸激酶(Syk)抑制剂的呋喃并[3,2 - d]嘧啶的合成与优化
Bioorg Med Chem Lett. 2016 Nov 15;26(22):5562-5567. doi: 10.1016/j.bmcl.2016.09.077. Epub 2016 Oct 11.
8
Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease.(S)-N-(1-(7-氟-2-(吡啶-2-基)喹啉-3-基)乙基)-9H-嘌呤-6-胺(AMG319)及相关 PI3Kδ抑制剂的发现及在炎症和自身免疫性疾病中的体内评价。
J Med Chem. 2015 Jan 8;58(1):480-511. doi: 10.1021/jm501624r. Epub 2014 Dec 3.
9
Effects of AS2541019, a novel selective PI3Kδ inhibitor, on antibody production and hamster to rat xenotransplantation.新型选择性 PI3Kδ 抑制剂 AS2541019 对抗体产生和仓鼠到大鼠异种移植的影响。
Eur J Pharmacol. 2018 May 5;826:179-186. doi: 10.1016/j.ejphar.2018.02.046. Epub 2018 Mar 5.
10
Synthesis and Evaluation of Novel 2H-Benzo[e]-[1,2,4]thiadiazine 1,1-Dioxide Derivatives as PI3Kδ Inhibitors.新型 2H-苯并[e]-[1,2,4]噻二嗪 1,1-二氧化物衍生物的合成与评价作为 PI3Kδ 抑制剂。
Molecules. 2019 Nov 25;24(23):4299. doi: 10.3390/molecules24234299.

引用本文的文献

1
The pyridazine heterocycle in molecular recognition and drug discovery.哒嗪杂环在分子识别与药物发现中的应用
Med Chem Res. 2023 Mar 15:1-69. doi: 10.1007/s00044-023-03035-9.
2
Structural Insights from Molecular Modeling of Isoindolin-1-One Derivatives as PI3Kγ Inhibitors against Gastric Carcinoma.异吲哚啉-1-酮衍生物作为PI3Kγ抑制剂抗胃癌的分子模拟结构见解
Biomedicines. 2022 Mar 30;10(4):813. doi: 10.3390/biomedicines10040813.
3
Construction of -Boc-2-Alkylaminoquinazolin-4(3)-Ones via a Three-Component, One-Pot Protocol Mediated by Copper(II) Chloride that Spares Enantiomeric Purity.
通过氯化铜介导的三组分一锅法构建 -Boc-2-烷基氨基喹唑啉-4(3)-酮,该方法可保留对映体纯度。
Adv Synth Catal. 2021 Mar 16;363(6):1638-1645. doi: 10.1002/adsc.202001279. Epub 2021 Feb 3.
4
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.基于喹唑啉-4-酮的羟肟酸类化合物的设计、合成与双 PI3K/HDAC 抑制活性评价。
J Med Chem. 2020 Apr 23;63(8):4256-4292. doi: 10.1021/acs.jmedchem.0c00193. Epub 2020 Apr 8.
5
Impact of Minor Structural Modifications on Properties of a Series of mTOR Inhibitors.微小结构修饰对一系列mTOR抑制剂性质的影响
ACS Med Chem Lett. 2019 Oct 4;10(11):1561-1567. doi: 10.1021/acsmedchemlett.9b00401. eCollection 2019 Nov 14.
6
Theoretical studies on the selectivity mechanisms of PI3Kδ inhibition with marketed idelalisib and its derivatives by 3D-QSAR, molecular docking, and molecular dynamics simulation.通过 3D-QSAR、分子对接和分子动力学模拟研究已上市的 PI3Kδ 抑制剂idelalisib 及其衍生物的选择性机制。
J Mol Model. 2019 Jul 23;25(8):242. doi: 10.1007/s00894-019-4129-x.
7
Structural Determinants of Isoform Selectivity in PI3K Inhibitors.PI3K 抑制剂的异构体选择性的结构决定因素。
Biomolecules. 2019 Feb 26;9(3):82. doi: 10.3390/biom9030082.
8
Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.在喹唑啉的4位引入吡咯烷氧基或哌啶氨基,从而得到新型的基于喹唑啉的磷酸肌醇3-激酶δ(PI3Kδ)抑制剂。
J Enzyme Inhib Med Chem. 2018 Dec;33(1):651-656. doi: 10.1080/14756366.2018.1444608.
9
Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.CDZ173(来尼利西布)的发现,代表了一类结构新颖的PI3Kδ选择性抑制剂。
ACS Med Chem Lett. 2017 Aug 25;8(9):975-980. doi: 10.1021/acsmedchemlett.7b00293. eCollection 2017 Sep 14.
10
Dose-Dependent Suppression of Cytokine production from T cells by a Novel Phosphoinositide 3-Kinase Delta Inhibitor.新型磷酸肌醇3激酶δ抑制剂对T细胞细胞因子产生的剂量依赖性抑制作用
Sci Rep. 2016 Jul 27;6:30384. doi: 10.1038/srep30384.